Skip to main content

Carolyn Glass

Associate Professor of Pathology
Pathology
214D Davison Building, 40 Duke Medicine Circle, Box #3712 DUHS, Durham, NC 27710

Research Interests


Dr. Glass received her BS in Neuroscience with Departmental Honors from the University of California at Los Angeles (UCLA) in 1997, before earning her MS from Baylor College of Medicine and MD from the University of Texas Medical Branch, Magna Cum Laude in 2007. Dr. Glass initially trained as a vascular surgeon with a focus on endovascular/interventional procedures through the Integrated Vascular Surgery Program at the University of Rochester Medical Center.  As a recipient of the NIH National Lung Blood Institute T32 Ruth Kirschstein National Service Research Award, she completed a Ph.D with a concentration in Genomics and Epigenetics in 2014.

 

Selected Grants


Ex Vivo Delivery of Viral-Mediated Gene Therapy for the Amelioration of Post-Transplant Rejection

ResearchCo Investigator · Awarded by National Institutes of Health · 2026 - 2031

NIH Recover: A Multisite Pathology Study of Post-Acute Sequelae of SARS-CoV2 Infection

ResearchPrincipal Investigator · Awarded by New York University · 2024 - 2027

Promoting Cardiac Allograft Tolerance with PD-L1 Gene Therapy in a Preclinical Porcine Model

ResearchCollaborator · Awarded by American Heart Association · 2026 - 2026

A digital polarization microscopy platform to enhance pathologist workflow

ResearchCo-Principal Investigator · Awarded by North Carolina Biotechnology Center · 2024 - 2026

Improving Cardiac Transplant Outcomes Through PD-L1 Overexpression Gene Therapy

FellowshipCollaborator · Awarded by Thoracic Surgery Foundation for Research and Education · 2023 - 2025

Epithelioid Mechanisms of Sarcoidosis

ResearchCollaborator · Awarded by Ann Theodore Foundation · 2022 - 2025

Improving Cardiac Transplant Outcomes Through PD-L1 Overexpression Gene Therapy

FellowshipCollaborator · Awarded by American Heart Association · 2023 - 2024

PSA level during midlife and undiagnosed prostate cancer at autopsy: Understanding tumor biology and racial disparities

ResearchCo Investigator · Awarded by Massachusetts General Hospital · 2022 - 2024

Exploiting targeted therapy-induced ATM dependence in residual lung tumors

ResearchCollaborator · Awarded by Department of Defense · 2021 - 2023

Turek - Step 2 Project

ResearchInvestigator · Awarded by Enzyvant · 2022 - 2023

Diffraction tomography for accurate digital pathology on a portable microscope

ResearchPrincipal Investigator · Awarded by AiriLabs LLC · 2022 - 2023

Identifying Epigenetic Biomarkers that Predict Response to Immunotherapy in Lung Cancer Patients

ResearchPrincipal Investigator · Awarded by Lung Cancer Initiative of North Carolina · 2020 - 2022

Increasing the Diagnostic Accuracy of Antibody Mediated

Clinical TrialCo Investigator · Awarded by CareDx, Inc. · 2020 - 2021

Fellowships, Gifts & Other Supported Research


The Duke Senescent Cell Evaluations in Normal Tissues (SCENT) Mapping Center · September 2021 - August 2027 Lead/SIte PI of Duke Biospecimen Core · Awarded by: National Institutes of Health · $3,300,000.00 To comprehensively identify and characterize the differences in senescent cells across the body, specifically colon and lung, across various states of human health, and across the lifespan. SenNet will provide publicly accessible atlases of senescent cells, the differences among them, and the molecules they secrete, using data collected from multiple human and model organism tissues and innovative tools/ technologies such as spatial transcriptomics that builds upon previous advances in single cell analysis.

External Relationships


  • California Institute of Technology
  • National Institute of Health (NIH)
  • North Carolina Biotechnology Center

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.